🇺🇸 InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) H

🇺🇸

NANJING, China, Aug. 28, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly…

Source: prnewswire

Country: United States